Business
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived
About this update from Sana Biotechnology, Inc.
[{"type":"image","alt":"Sana Biotechnology, Inc","displaySize":"","headline":null,"caption":"Sana Biotechnology, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PW1btp2owOxzuDhhLJX9Mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e","width":300,"height":85}},"lazy":false},{"type":"text","content":"Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant","length":283,"tagName":"p"},{"type":"text","content":"New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study","length":110,"tagName":"p"},{"type":"text","content":"Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived therapy, as a one-time treatment for patients with type 1 diabetes, with a goal of normal blood glucose, with no insulin and no immunosuppression","length":251,"tagName":"p"},{"type":"text","content":"Made significant progress with SC451 across manufacturing, regulatory, and clinical trial preparedness, including the non-clinical testing plan and manufacture of the master cell bank","length":183,"tagName":"p"},{"type":"text","content":"Expect to file investigational new drug application (IND) for SC451 in type 1 diabetes and begin Phase 1 trial as early as this year","length":132,"tagName":"p"},{"type":"text","content":"Expect to generate first-in-human data in blood cancers as early as this year for the next-generation in vivo CAR T product candidate, SG293, a CD8-targeted fusosome that delivers a CD19-directed CAR","length":199,"tagName":"p"},{"type":"text","content":"Demonstrated deep B-cell depletion and immune reset with a single treatment in non-human primates with surrogate SG293","length":118,"tagName":"p"},{"type":"text","content":"Raised aggregate gross proceeds of $133.7 million from sales of common stock through Sana’s at the market offering facility (ATM) and equity financing in 2025","lengt...